Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORCEPT-E 1/35 28 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen (ethinyl estradiol) and progestin (norethindrone) contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, and alters endometrial lining.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Oral contraceptive
Prevention of pregnancy (FDA-approved)
1 tablet orally once daily for 21 days, followed by 7 days of placebo tablets.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 5-14 hours; ethinyl estradiol: 13-27 hours. The terminal half-life of norethindrone is about 10 hours, allowing once-daily dosing; ethinyl estradiol's longer half-life contributes to steady-state concentrations within 3-5 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily metabolized by CYP3A4; norethindrone: primarily metabolized by CYP3A4 and CYP2C9.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal (primarily as metabolites) and fecal; approximately 50-60% excreted in urine, 30-40% in feces. Ethinyl estradiol and norethindrone are extensively metabolized via hydroxylation and conjugation; glucuronide and sulfate conjugates are eliminated in urine and bile.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: >97% bound to albumin and SHBG; ethinyl estradiol: >97% bound to albumin. Ethinyl estradiol also binds to SHBG with lower affinity.
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: approximately 3.5 L/kg; ethinyl estradiol: approximately 2.5 L/kg. These values reflect extensive tissue distribution and binding to tissues such as breast, uterus, and adipose.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Norethindrone ~64% (first-pass metabolism); ethinyl estradiol ~40-50% (extensive first-pass metabolism). Factors such as food and individual differences may affect bioavailability.
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in acute renal disease or marked renal impairment.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in severe hepatic disease or liver tumors (benign or malignant). Use with caution in mild to moderate hepatic impairment; dose adjustment generally not required but monitor for adverse effects.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. After menarche, use same adult dosing schedule.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
No specific dose adjustment; use with caution due to increased risk of thromboembolic disorders and cardiovascular events in women over 35 who smoke.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events (thrombosis, stroke, myocardial infarction) from combination oral contraceptives, especially in women over 35 and heavy smokers (>15 cigarettes/day).
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (DVT, PE, stroke, MI),Hepatic tumors,Hypertension,Gallbladder disease,Carbohydrate/lipid metabolism effects,Ocular lesions (retinal thrombosis),Hereditary angioedema,Chloasma,Depression
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,History of DVT/PE,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice does not affect ethinyl estradiol. Avoid St. John's wort (herbal supplement) as it reduces contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: Increased risk of neural tube defects, cardiovascular malformations, and limb reduction defects if inadvertently exposed to the progestin component (norethindrone) at high doses. Second and third trimesters: No evidence of teratogenicity from estrogen-progestin combinations; however, androgenic effects (pseudohermaphroditism in female fetuses) have been reported with high doses of progestins. Overall, combination oral contraceptives are contraindicated in pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of ethinyl estradiol and norethindrone are excreted into breast milk (M/P ratio for ethinyl estradiol approximately 0.75; for norethindrone, about 0.66). Use may reduce milk production and quality, especially in early postpartum. Avoid in nursing mothers unless essential; alternative contraception recommended.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated during pregnancy. No dose adjustments recommended as drug should be stopped immediately upon pregnancy diagnosis.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
NORCEPT-E 1/35 28 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norethindrone 1 mg. It is indicated for contraception and may be used off-label for menstrual disorders. Pearl: Counsel patients that missed pills increase pregnancy risk; refer to prescribing information for missed dose instructions. Monitor for thromboembolic events, especially in smokers over 35. Drug interactions: rifampin, certain anticonvulsants (e.g., phenytoin, carbamazepine), and St. John's wort reduce efficacy. Breakthrough bleeding common in first 3 cycles; if persistent, evaluate for non-compliance or alternative causes.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time, preferably after an evening meal or at bedtime to minimize nausea.,Missed pill? Take as soon as remembered; if >48 hours, use backup contraception (condoms) for 7 days and consult the package insert.,Report immediately: severe leg pain/chest pain/sudden shortness of breath (signs of blood clot), severe headache, vision changes, or jaundice.,Smoking increases risk of serious cardiovascular side effects; avoid smoking especially if over 35.,May decrease efficacy with certain antibiotics (non-rifampin) – use backup contraception during antibiotic course and for 7 days after.,Do not take if pregnant, breastfeeding, or have history of blood clots, stroke, breast cancer, liver disease, or migraine with aura.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORCEPT-E 1/35 28 vs AFIRMELLE, answered by our medical review team.
NORCEPT-E 1/35 28 is a Combined Oral Contraceptive that works by Combination estrogen (ethinyl estradiol) and progestin (norethindrone) contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, and alters endometrial lining.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORCEPT-E 1/35 28 and AFIRMELLE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORCEPT-E 1/35 28 is: 1 tablet orally once daily for 21 days, followed by 7 days of placebo tablets.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORCEPT-E 1/35 28 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORCEPT-E 1/35 28 is classified as Category C. First trimester: Increased risk of neural tube defects, cardiovascular malformations, and limb reduction defects if inadvertently exposed to the progestin component (norethindrone). AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.